Engineering Stem Cells for Islet Replacement Therapy: Recent Advances and Barriers for Clinical Translation.

Area of Science:

• Regenerative Medicine
• Endocrinology
• Cell Biology

Background:

• Diabetes mellitus is a major global health burden, characterized by beta-cell destruction or dysfunction.
• Current treatments improve glycemic control but do not restore functional beta-cell mass.
• Regenerative medicine strategies focus on protecting, regenerating, or replacing insulin-producing cells.

Purpose of the Study:

• To review advances in engineering stem cell-derived insulin-producing cells for islet replacement therapy.
• To highlight differentiation strategies and immunoprotective approaches.
• To identify translational barriers for durable beta-cell replacement.

Main Methods:

• Review of current literature on stem cell differentiation for beta-cell generation.
• Analysis of immunoprotective strategies for transplanted cells.
• Examination of challenges in scalable manufacturing and clinical engraftment.

Main Results:

• Stem cell-based approaches can generate glucose-responsive beta-like cells.
• Significant challenges remain in achieving full functional maturation and immune protection.
• Scalable manufacturing and durable engraftment are critical hurdles for clinical translation.

Conclusions:

• Engineering stem cell-derived beta-cells is a promising avenue for diabetes treatment.
• Overcoming challenges in maturation, immune evasion, and manufacturing is essential for therapeutic success.
• Further research is needed to address translational barriers for widespread clinical application.